Neurovascular Access Systems Patents: Top Companies & Trends 2026
Neurovascular access system patents: who is filing, and where the field is still open
29.5% concentration at the top. The five leading assignees account for 1,111 of 3,771 records in scope — a real lead, but not a lock on the field. Annual filings ran from 161 in 2017 to a peak of 335 in 2020. The three-year span from 2021 (267) to 2024 (132) — the most recent year the dataset can treat as complete — shows a 51% decline. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still filling in and should not be read as a continuation of that decline.
- 1COVIDIEN LP8.5%
- 2BOSTON SCIENTIFIC SCIMED INC7.5%
- 3ROUTE 92 MEDICAL INC6.7%
- 4IMPERATIVE CARE INC3.9%
- 5EVALVE2.9%
See the full neurovascular access systems analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in neurovascular access systems?
The ranked list in this dataset covers 100 assignees, with the leader holding 319 records and the fifth-place holder 111. The top five combined account for 29.5% of all 3,771 records in scope, and the top ten account for 41.2%. That still leaves a majority of the field spread across companies and inventors outside the ranked leaders, so leadership in this space is meaningful but not exclusive.
Is patent filing in neurovascular access catheters slowing down?
Filings peaked in 2020 at 335 and fell from 267 in 2021 to 132 in 2024, a 51% decline over that span — the most recent three-year period the dataset can treat as complete. Publication typically lags actual filing by around 18 months, so 2025 and 2026 counts are still incomplete and should not be read as continuing the same slope. The honest read is a real pullback in filing volume through 2024, not a verdict on where filing stands today.
What technology areas dominate neurovascular access patent claims?
A61B, covering diagnosis and surgery devices, appears in 66.7% of the 3,771 records in scope, and A61M, covering devices for body fluids, appears in 50.4%. A61F, implants and prostheses, sits at 34.7%. Sterilisation, electrotherapy, medicinal preparations, materials testing and plastics-shaping classes each cover under 4% of records, marking them as comparatively under-claimed relative to the delivery-mechanics core.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Neurovascular Access Systems covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.